Abstract
Raynaud’s phenomenon (RP) in the majority of patients is idiopathic (primary RP; PRP), however in approximately 10–20 % of patients there is an underlying driving aetiology (secondary RP; SRP). Recognition of SRP (unlike PRP) is of utmost importance as it may progress to irreversible tissue damage and alert the physician to the presence of an underlying serious disease process. RP secondary to connective tissue disease and to trauma has been discussed in the previous two chapters. The purpose of this chapter is to explore the evidence base for the “other” widely recognised causes of SRP (Table 10.1), namely, carpal tunnel syndrome, drugs and toxins, metabolic and haematological abnormalities and malignancy-related.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ADHD:
-
Attention deficit hyperactivity disorder
- CsA:
-
Cyclosporine A
- ET:
-
Endothelin
- IFN-α:
-
Interferon-alpha
- IFN-β:
-
Interferon-beta
- IFN-γ:
-
Interferon-gamma
- MS:
-
Multiple sclerosis
- OR:
-
Odds ratio
- RP:
-
Raynaud’s phenomenon
- SSc:
-
Systemic sclerosis
- VCM:
-
Vinyl chloride monomer
References
Pal B, Keenan J, Misra HN, Moussa K, Morris J. Raynaud’s phenomenon in idiopathic carpal tunnel syndrome. Scand J Rheumatol. 1996;25(3): 143–5.
Garland H, Bradshaw JP, Clark JM. Compression of median nerve in carpal tunnel and its relation to acroparaesthesiae. Br Med J. 1957;1(5021):730–4.
Waller DG, Dathan JR. Raynaud’s syndrome and carpal tunnel syndrome. Postgrad Med J. 1985;61(712):161–2.
Chung MS, Gong HS, Baek GH. Prevalence of Raynaud’s phenomenon in patients with idiopathic carpal tunnel syndrome. J Bone Joint Surg (Br). 1999;81(6):1017–9.
Hartmann P, Mohokum M, Schlattmann P. The association of Raynaud’s syndrome with carpal tunnel syndrome: a meta-analysis. Rheumatol Int. 2012;32(3):569–74.
Chung MS, Gong HS, Baek GH. Raynaud’s phenomenon in idiopathic carpal tunnel syndrome: postoperative alteration in its prevalence. J Bone Joint Surg (Br). 2000;82(6):818–9.
Mondelli M, Romano C, De Stefano R, Cioni R. Nerve conduction velocity study of the upper limb in Raynaud’s phenomenon. Rheumatol Int. 2000;19(5):165–9.
Lee P, Bruni JSS. Neurological manifestations in systemic sclerosis (scleroderma). J Rheumatol. 1984;11(4):480–3.
Machet L, Vaillant L, Machet MC, Esteve E, Muller C, Khallouf R, Lorette G. Carpal tunnel syndrome and systemic sclerosis. Dermatology. 1992;185(2):101–3.
Sukenik S, Abarbanel JM, Buskila D, Potashnik G, Horowitz J. Impotence, carpal tunnel syndrome and peripheral neuropathy as presenting symptoms in progressive systemic sclerosis. J Rheumatol. 1987;14(3):641–3.
Deray G, Le Hoang P, Achour L, Hornych A, Landault C, Caraillon A. Cyclosporin and Raynaud phenomenon. Lancet. 1986;2(8515):1092–3.
Davenport A. The effect of renal transplantation and treatment with cyclosporin A on the prevalence of Raynaud’s phenomenon. Clin Transpl. 1993;7(1):4–8.
Sharma AK, Sunil S, Rustom R, Bone JM, Hammad A, Bakran A, et al. Cyclosporin A-related Raynaud’s phenomenon in a renal transplant recipient. Transpl Int. 2002;15(9–10):517–8.
Arinsoy T, Derici U, Yuksel A, Reis KA, Sindel S. Cyclosporine – a treatment and a rare complication: Raynaud’s phenomenon. Int J Clin Pract. 2005;59(7):863–4.
Grieff M, Loertscher R, Shohaib SA, Stewart DJ. Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants. Transplantation. 1993;56(4):880–4.
Piquard F, Geny B, Elero B, Canguilhem B, Mettauer B, Epailly E, et al. Role of immunosuppressive therapy in neuroendocrine activation after human heart, renal, and liver transplantation. Transplant Proc. 1998;30(5):2124–6.
Doutreleau S, Gautherie M, Lonsdorfer E, Rouyer O, Epailly E, Eisenmann B, et al. Usefulness of finger thermography to assess cyclosporine toxicity after heart transplantation. Transplant Proc. 2001; 33(7–8):3318–9.
Asberg A, Berg KJ, Hartmann A. Each administration of cyclosporin A enhances skin microvascular reactivity in renal transplant recipients. Microvasc Res. 2000;60(2):81–90.
Filaci G, Cutolo M, Scudeletti M, Castagneto C, Derchi L, Gianrossi R, et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology (Oxford). 1999;38(10):992–6.
Filaci G, Cutolo M, Basso M, Murdaca G, Derchi L, Gianrossi R, et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford). 2001;40(12):1431–2.
Clements PJ, Lachenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum. 1993;36(1):75–83.
Arslan M, Ozyilkan E, Kayhan B, Telatar H. Raynaud’s phenomenon associated with alpha-interferon therapy. J Intern Med. 1994;235(5):503.
Iorio R, Spagnuolo MI, Sepe A, Zoccali S, Alessio M, Vegnente A. Severe Raynaud’s phenomenon with chronic hepatis C disease treated with interferon. Pediatr Infect Dis J. 2003;22(2):195–7.
Bachmeyer C, Farge D, Gluckman E, Miclea JM, Aractingi S. Raynaud’s phenomenon and digital necrosis induced by interferon-alpha. Br J Dermatol. 1996;135(3):481–3.
Creutzig A, Freund M, Caspary L, Alexander K. Microangiopathy in patients with chronic myelogenous leukemia treated with interferon. Microvasc Res. 1996;52(3):288–92.
Sachithanandan A, Cuthbert RJ, Barros d’Sa AA. Interferon induced severe digital ischaemia in chronic myeloid leukaemia – successful treatment using ketanserin. Eur J Vasc Endovasc Surg. 2001;22(5):474–6.
Kruit WH, Eggermont AM, Stoter G. Interferon-alpha induced Raynaud’s syndrome. Ann Oncol. 2000;11(11):1501–2.
Linden D. Severe Raynaud’s phenomenon associated with interferon-beta treatment for multiple sclerosis. Lancet. 1998;352(9131):878–9.
Airo’ P, Scarsi M, Rossi M, Mondini M. Onset and enhancement of systemic sclerosis after treatments for multiple sclerosis. Rheumatol Int. 2008;28(7):703–7.
Hügle T, Gratzl S, Daikeler T, Frey D, Tyndall A, Walker UA. Sclerosing skin disorders in association with multiple sclerosis. Coincidence, underlying autoimmune pathology or interferon induced? Ann Rheum Dis. 2009;68(1):47–50.
Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, et al. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol. 1996;23(4):654–8.
Molteni M, Della Bella S, Mascagni B, Bazzi S, Zulian C, Compasso S, et al. Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud’s phenomenon. Clin Exp Immunol. 1999;116(1):164–8.
Pope J. Treatment of systemic sclerosis. Curr Opin Rheumatol. 1993;5(6):792–801.
Mohokum M, Hartmann P, Schlattmann P. Association of Raynaud’s syndrome with interferons. A meta-analysis. Int Angiol. 2012;31(5):408–13.
Teutsch C, Lipton A, Harvey HA. Raynaud’s phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep. 1977;61(5):925–6.
Soble AR. Chronic bleomycin-associated Raynaud’s phenomenon. Cancer Treat Rep. 1978;62(4):570.
Chernicoff DP, Bukowski RM, Young JR. Raynaud’s phenomenon after bleomycin treatment. Cancer Treat Rep. 1978;62(4):570–1.
Paty Jr JG, Ruffner Jr BW. Bleomycin-vinblastine associated Raynaud’s phenomenon. J Rheumatol. 1980;7(6):927–8.
Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary Raynaud’s phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer. 1995;31A(13–14):2229–38.
Fosså SD, Lehne G, Heimdal K, Theodorsen L. Clinical and biochemical long-term toxicity after postoperative cisplatin-based chemotherapy in patients with low-stage testicular cancer. Oncology. 1995;52(4):300–5.
Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med. 1981;95(3):288–92.
Hansen SW, Olsen N. Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol. 1989;7(7):940–2.
Hansen SW, Olsen N, Rossing N, Rørth M. Vascular toxicity and the mechanism underlying Raynaud’s phenomenon in patients treated with cisplatin, vinblastine and bleomycin. Ann Oncol. 1990;1(4):289–92.
Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer. 1985;56(12):2765–70.
Dunlop PR, Hendy-Ibbs PM. Raynaud’s phenomenon and cryoglobulinemia during chemotherapy for testicular carcinoma. Cancer Treat Rep. 1983;67(3):317–8.
Snauwaert J, Degreef H. Bleomycin-induced Raynaud’s phenomenon and acral sclerosis. Dermatologica. 1984;169(4):172–4.
Elomaa I, Pajunen M, Virkkunen P. Raynaud’s phenomenon progressing to gangrene after vincristine and bleomycin therapy. Acta Med Scand. 1984; 216(3):323–6.
McGrath SE, Webb A, Walker-Bone K. Bleomycin-induced Raynaud’s phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion. J Clin Oncol. 2013;31(4):e51–2.
Caumes E, Katlama C, Guermonprez G, Bournerias I, Danis M, Gentilini M. Cutaneous side-effects of bleomycin in AIDS patients with Kaposi’s sarcoma. Lancet. 1990;336(8730):1593.
Fertakos RJ, Mintzer DM. Digital gangrene following chemotherapy for AIDS-related Kaposi’s sarcoma. Am J Med. 1992;93(5):581–2.
Vayssairat M, Gaitz JP, Bamberger N. Digital gangrene, HIV infection and bleomycin treatment. J Rheumatol. 1993;20(5):921.
Chakfe N, Rey D, Sibilia J, Bronner JF, Beaufigeau M, Partisani M, et al. Thoracoscopic sympathectomy for ischaemic lesions related to bleomycin therapy for acquired immune deficiency syndrome-related Kaposi’s sarcoma. Eur J Vasc Endovasc Surg. 1999;17(2):175–7.
Hladunewich M, Sawka C, Fam A, Franssen E. Raynaud’s phenomenon and digital gangrene as a consequence of treatment for Kaposi’s sarcoma. J Rheumatol. 1997;24(12):2371–5.
Reiser M, Bruns C, Hartmann P, Salzberger B, Diehl V, Fätkenheuer G. Raynaud’s phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi’s sarcoma. Eur J Clin Microbiol Infect Dis. 1998;17(1):58–60.
von Gunten CF, Roth EL, Von Roenn JH. Raynaud phenomenon in three patients with acquired immune deficiency syndrome-related Kaposi sarcoma treated with bleomycin. Cancer. 1993;72(6):2004–6.
Smith EA, Harper FE, LeRoy EC. Raynaud’s phenomenon of a single digit following local intradermal bleomycin sulfate injection. Arthritis Rheum. 1985;28(4):459–61.
Epstein E. Persisting Raynaud’s phenomenon following intralesional bleomycin treatment of finger warts. J Am Acad Dermatol. 1985;13(3):468–71.
Vanhooteghem O, Richert B, de la Brassinne M. Raynaud phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin. Pediatr Dermatol. 2001;18(3):249–51.
McGuire WA, Passo MH, Weetman RM. Chemotherapy-associated Raynaud’s phenomenon in a two-year-old girl. Med Pediatr Oncol. 1985;13(6):392–4.
Mohokum M, Hartmann P, Schlattmann P. The association of Raynaud’s syndrome with cisplatin-based chemotherapy - a meta-analysis. Eur J Intern Med. 2012;23(7):594–8.
Seishima M, Izumi T, Kanoh H. Raynaud’s phenomenon possibly induced by a compound drug of tegafur and uracil. Eur J Dermatol. 2000;10(1):55–8.
Zaima C, Kanai M, Ishikawa S, Kawaguchi Y, Masui T, Mori Y, et al. A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. Jpn J Clin Oncol. 2011;41(6):803–6.
Clowse ME, Wigley FM. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol. 2003;30(6):1341–3.
Mohokum M, Hartmann P, Schlattmann P. The association of Raynaud syndrome with β-blockers: a meta-analysis. Angiology. 2012;63(7):535–40.
Pyykkö I, Färkkilä M. Clonidine in the treatment of vibration-induced white fingers. Scand J Work Environ Health. 1982;8(4):294–9.
Coffman JD, Cohen RA. Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits. Eur J Clin Invest. 1988;18(3):309–13.
Coffman JD, Cohen RA. Alpha-adrenergic and serotonergic mechanisms in the human digit. J Cardiovasc Pharmacol. 1988;11 Suppl 1:S49–53.
Freedman RR, Sabharal SC, Desai N, Wenig P, Mayes M. Increased alpha-adrenergic responsiveness in idiopathic Raynaud’s disease. Arthritis Rheum. 1989;32(1):61–5.
Freedman RR, Sabharwal SC, Moten M, Migály P. Local temperature modulates alpha 1- and alpha 2-adrenergic vasoconstriction in men. Am J Physiol. 1992;263(4 Pt 2):H1197–200.
Freedman RR, Moten M, Migály P, Mayes M. Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud’s disease. Arthritis Rheum. 1993;36(5):685–90.
Freedman RR, Girgis R, Mayes MD. Endothelial and adrenergic dysfunction in Raynaud’s phenomenon and scleroderma. J Rheumatol. 1999;26(11):2386–8.
Dahlöf C, Maassen Van Den Brink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache. 2012;52(4):707–14.
Koehler PJ, Tfelt-Hansen PC. History of methysergide in migraine. Cephalalgia. 2008;28(11):1126–35.
Robb LG. Severe vasospasm following ergot administration. West J Med. 1975;123(3):231–5.
Goldman W, Seltzer R, Reuman P. Association between treatment with central nervous system stimulants and Raynaud’s syndrome in children: a retrospective case-control study of rheumatology patients. Arthritis Rheum. 2008;58(2):563–6.
Balbir-Gurman A, Braun-Moscovici Y, Nahir AM. Cocaine-induced Raynaud’s phenomenon and ischaemic finger necrosis. Clin Rheumatol. 2001;20(5):376–8.
Sullivan JT, Becker PM, Preston KL, Wise RA, Wigely FM, Testa MP, et al. Cocaine effects on digital blood flow and diffusing capacity for carbon monoxide among chronic cocaine users. Am J Med. 1997;102(3):232–8.
Attoussi S, Faulkner ML, Oso A, Umoru B. Cocaine-induced scleroderma and scleroderma renal crisis. South Med J. 1998;91(10):961–3.
Noël B. Cocaine and arsenic-induced Raynaud’s phenomenon. Clin Rheumatol. 2002;21(4):343–4.
Lopez V, Chamoux A, Tempier M, Thiel H, Ughetto S, Trousselard M, et al. The long-term effects of occupational exposure to vinyl chloride monomer on microcirculation: a cross-sectional study 15 years after retirement. BMJ Open. 2013;3:e002785. doi:10.1136/bmjopen-2013-002785.
Studnicka MJ, Menzinger G, Drlicek M, Maruna H, Neumann MG. Pneumoconiosis and systemic sclerosis following 10 years of exposure to polyvinyl chloride dust. Thorax. 1995;50(5):583–5.
Harris DK, Adams WG. Acro-osteolysis occurring in men engaged in the polymerization of vinyl chloride. Br Med J. 1967;3(5567):712–4.
Wilson RH, McCormick WE, Tatum CF, Creech JL. Occupational acroosteolysis: report of 31 cases. JAMA. 1967;201(8):577–81.
Maricq HR, Johnson MN, Whetstone CL, LeRoy EC. Capillary abnormalities in polyvinyl chloride production workers. Examination by in vivo microscopy. JAMA. 1976;236:1368–71.
Fontana L, Baietto M, Becker F, Catilina P. Clinical and capillaroscopic study of Raynaud’s phenomenon in retired patients previously exposed to vinyl chloride monomer. J Mal Vasc. 1995;20(4):268–73.
Black CM, Welsh KI, Walker AE, Bernstein RM, Catoggio LJ, McGregor AR, et al. Genetic susceptibility to scleroderma-like syndrome induced by vinyl chloride. Lancet. 1983;1(8314–5):53–5.
Maricq HR, Darke CS, Archibald RM, LeRoy EC. In vivo observations of skin capillaries in workers exposed to vinyl chloride. An English-American comparison. Br J Ind Med. 1978;35:1–7.
Langauer-Lewowicka H. Nailfolds capillary abnormalities in polyvinyl chloride production workers. Int Arch Occup Environ Health. 1983;51:337–40.
Shagan BP, Friedman SA. Raynaud’s phenomenon in hypothyroidism. Angiology. 1976;27(1):19–25.
Shagan BP, Friedman SA. Raynaud’s phenomenon and thyroid deficiency. Arch Intern Med. 1980; 140(6):832–3.
Batthish M, Costigan C, Killeen OG. Raynaud’s phenomenon as a presenting feature of hypothyroidism in an 11-year-old girl. J Rheumatol. 2009; 36(1):203–4.
Nielsen SL, Parving HH, Hansen JE. Myxoedema and Raynaud’s phenomenon. Acta Endocrinol (Copenh). 1982;101(1):32–4.
Lateiwish AM, Fehér J, Baraczka K, Rácz K, Kiss R, Gláz E. Remission of Raynaud’s phenomenon after L-thyroxine therapy in a patient with hypothyroidism. J Endocrinol Invest. 1992;15(1):49–51.
Sipilä R, Viitasalo K, Heikkilä J. Hypothyroidism, Raynaud’s phenomenon, and acute myocardial infarction in a young woman. Clin Cardiol. 1983; 6(6):304–6.
Biró E, Szekanecz Z, Czirják L, Dankó K, Kiss E, Szabó NA, et al. Association of systemic and thyroid autoimmune diseases. Clin Rheumatol. 2006;25(2):240–5.
Shoaleh-var M, Momtaz AH, Jamshidi C. Scleroderma and hyperthyroidism. Report of a case. JAMA. 1976;235(7):752–3.
Gordon MB, Klein I, Dekker A, Rodnan GP, Medsger Jr TA. Thyroid disease in progressive systemic sclerosis: increased frequency of glandular fibrosis and hypothyroidism. Ann Intern Med. 1981; 95(4):431–5.
Kahl LE, Medsger Jr TA, Klein I. Prospective evaluation of thyroid function in patients with systemic sclerosis (scleroderma). J Rheumatol. 1986;13(1):103–7.
Serup J, Hangdrup H. Thyroid hormones in generalized scleroderma. A controlled study. Acta Derm Venereol. 1986;66(1):35–8.
Nicholson D, White S, Lipson A, Jacobs RP, Borenstein DG. Progressive systemic sclerosis and Graves’ disease. Report of three cases. Arch Intern Med. 1986;146(12):2350–2.
De Keyser L, Narhi DC, Furst DE, Huberman AK, Ross R, Clements J, et al. Thyroid dysfunction in a prospectively followed series of patients with progressive systemic sclerosis. J Endocrinol Invest. 1990;13(2):161–9.
Molnár I, Balázs C, Szabó E, Czirják L. Anti-thyroid antibodies and hypothyroidism in systemic sclerosis. J Endocrinol Invest. 1992;15(4):311.
Anzai H, Tajima S. Systemic scleroderma associated with Graves’ disease. J Dermatol. 1996;23(12):896–8.
Gokula RM, Gupta AK, Shirley SE, Coard K, Ramphal PS. Scleroderma with cardiac tamponade, hyperthyroidism and incidental papillary thyroid carcinoma. West Indian Med J. 2002;51(3):188–90.
Kamei N, Yamane K, Yamashita Y, Nakanishi S, Watanabe H, Fujikawa R, et al. Anti-Ku antibody-positive scleroderma-dermatomyositis overlap syndrome developing Graves’ disease and immune thrombocytopenic purpura. Intern Med. 2002;41(12):1199–203.
Nakamura T, Higashi S, Tomoda K, Tsukano M, Sugi K. Primary biliary cirrhosis (PBC)-CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin Rheumatol. 2007;26(4):596–600.
Katsantonis JC, Protopsaltis J, Kokkoris S, Brestas P, Aroni K, Tournis S. Systemic sclerosis associated with generalized vasculitis and hypopituitarism. Rheumatol Int. 2008;28(11):1165–8.
Wimmersberger Y, Zuercher D. Graves’ disease associated with primary systemic sclerosis. Orbit. 2009;28(4):262–3.
Antonelli A, Ferri C, Fallahi P, Cazzato M, Ferrari SM, Sebastiani M, et al. Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis. Eur J Endocrinol. 2007;156(4):431–7.
No authors listed (demonstrated at the postgraduate medical school of London). A Complicated Case of Carcinoid Disease. Br Med J 1963;1(5342): 1397–402.
Durward G, Blackford S, Roberts D, Jones MK. Cutaneous scleroderma in association with carcinoid syndrome. Postgrad Med J. 1995;71(835):299–300.
Jiménez-Sáenz M, Ortiz-Moyano C, Cantillana-Martinez J, Herrerías-Gutierrez JM. Recurrent abdominal pain in systemic sclerosis: not always intestinal pseudo-obstruction. J Eur Acad Dermatol Venereol. 2003;17(5):605–7.
Bell HK, Poston GJ, Vora J, Wilson NJ. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol. 2005;152(1):71–5.
Keles Z, Onur O, Carlioglu A, Sarifakioglu E. Pheochromocytoma in a patient with a preliminary diagnosis of Raynaud’s phenomenon. Scand J Rheumatol. 2010;39(6):523–4.
Balbir-Gurman A, Menahem Nahir A, Rozin A, Markovits D, Braun-Moscovici Y. Toe necrosis and acute myocardial infarction precipitated by a pheochromocytoma in a patient with systemic sclerosis. J Clin Rheumatol. 2007;13(6):331–3.
Bardwick PA, Zvaifler NJ, Gill GN, Newman D, Greenway GD, Resnick DL. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore). 1980;59(4):311–22.
Dispenzieri A. POEMS syndrome. Blood Rev. 2007;21(6):285–99.
Miest RY, Comfere NI, Dispenzieri A, Lohse CM, el-Azhary RA. Cutaneous manifestations in patients with POEMS syndrome. Int J Dermatol. 2013; 52(11):1349–56.
Lesprit P, Godeau B, Authier FJ, Soubrier M, Zuber M, Larroche C, et al. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med. 1998;157(3 Pt 1): 907–11.
Li J, Tian Z, Zheng HY, Zhang W, Duan MH, Liu YT, et al. Pulmonary hypertension in POEMS syndrome. Haematologica. 2013;98(3):393–8.
Jouve P, Humbert M, Chauveheid MP, Jaïs X, Papo T. POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respir Med. 2007;101(2):353–5.
Paciocco G, Bossone E, Erba H, Rubenfire M. Reversible pulmonary hypertension in POEMS syndrome–another etiology of triggered pulmonary vasculopathy? Can J Cardiol. 2000;16(8):1007–12.
Toussaint P, Sibaud V, Labbe L, Geniaux M. POEMS syndrome revealed by a scleroderma-like skin thickening. Ann Dermatol Venereol. 2000;127(1):73–6.
Hasegawa M, Orito H, Yamamoto K, Matsushita T, Hamaguchi Y, Fujimoto M, et al. Skin sclerosis as a manifestation of POEMS syndrome. J Dermatol. 2012;39(11):922–6.
Barete S, Mouawad R, Choquet S, Viala K, Leblond V, Musset L, et al. Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome: impact of autologous hematopoietic stem cell transplantation. Arch Dermatol. 2010;146(6):615–23.
McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. B J Haematol. 2005;130(2):174–95.
Messinezy M, Pearson TC. ABC of clinical haematology. Polycythaemia, primary (essential) thrombocythaemia and myelofibrosis. BMJ. 1997;314(7080):587.
Schafer AI. Thrombocytosis. N Engl J Med. 2004;350(12):1211–9.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–97.
Itin PH, Winkelmann RK. Cutaneous manifestations in patients with essential thrombocythemia. J Am Acad Dermatol. 1991;24(1):59–63.
Landolfi R, Gennaro LD. Thrombosis in myeloproliferative and myelodysplastic syndromes. Hematology. 2012;17 Suppl 1:S174–6.
Papadonikolakis A, Chloros GD, Smith BP, Koman LA. Digital ischemia due to essential thrombocythemia: a case report. J Hand Surg [Am]. 2007;32(7):1053–7.
Van Genderen PJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 1997;23(4):357–63.
Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol. 2000;43(5 pt 1):841–7.
Cook L, Macdonald DH. Management of paraproteinaemia. Postgrad Med J. 2007;83(978):217–23.
Jones RR. The cutaneous manifestations of paraproteinaemia. Br J Dermatol. 1980;103(3):335–45.
Morra E. Cryoglobulinemia. Hematology Am Soc Hematol Educ Program 2005: 368-72
Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002;55(1):4–13.
Vermeersch P, Gijbels K, Mariën G, Lunn R, Egner W, White P, et al. A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins. Clin Chem. 2008;54(1):39–43.
den Hollander JG, Swaak AJG. Essential cryoglobulinaemia (type 1) in three patients characterised by Raynaud’s phenomenon, arthralgia-arthritis, and skin lesions. Ann Rheum Dis. 2002;61(1):88–9.
Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet. 2012;379(9813):348–60.
Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A, et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. QJM. 1995;88(2):115–26.
Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Puccini R, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33(6):355–74.
Giuggioli D, Manfredi A, Colaci M, Manzini CU, Antonelli A, Ferri C. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev. 2013;12(11):1058–63.
Soyfoo MS, Goubella A, Cogan E, Wautrecht JC, Ocmant A, Stordeur P. Clinical significance of Cryofibrinogenemia: possible pathophysiological link with Rayanud’s phenomenon. J Rheumatol. 2012;39(1):119–24.
Michaud M, Pourrat J. Cryofibrinogenemia. J Clin Rheumatol. 2013;19(3):142–8.
Saadoun D, Elalamy I, Ghillani-Dalbin P, Sene D, Delluc A, Cacoub P. Cryofibrinogenemia: new insights into clinical and pathogenic features. Am J Med. 2009;122(12):1128–35.
Blain H, Cacoub P, Musset L, Costedoat-Chalumeau N, Silberstein C, Chosidow O. Cryofibrinogenaemia: a study of 49 patients. Clin Exp Immunol. 2000;120(2):253–60.
Petz LD. Cold antibody autoimmune hemolytic anemias. Blood Rev. 2008;22(1):1–15.
Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114–21.
Sinha A, Richardson G, Patel RT. Coldagglutinin related acrocyanosis and paroxysmal haemolysis. Eur J Vasc Endovasc Surg. 2005;30(5):563–5.
Mitchell AB, Pergrum GD, Gill AM. Cold agglutinin disease with Raynaud’s phenomenon. Proc R Soc Med. 1974;67(2):113–5.
Kröger K, Billen T, Neuhaus G, Santosa F, Buss C, Kreuzfelder E, et al. Relevance of low titers of cryoglobulins and cold-agglutinins in patients with isolated Raynaud phenomenon. Clin Hemorheol Microcirc. 2001;24(3):167–74.
Espinosa G, Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality. Nat Rev Rheumatol. 2010;6(5):296–300.
Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498–509.
Shemirani AH, Szomják E, Balogh E, András C, Kovács D, Acs J, Csiki Z. Polymorphism of clotting factors in Hungarian patients with Raynaud’s phenomenon. Blood Coagul Fibrinolysis. 2011;22(1):56–9.
Naldi L, Locati F, Marchesi L, Cortelazzo S, Finazzi G, Galli M, et al. Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study. Ann Rheum Dis. 1993;52(3):219–22.
Vayssairat M, Abuaf N, Baudot N, Deschamps A, Gaitz JP. Abnormal IgG cardiolipin antibody titers in patients with Raynaud’s phenomenon and/or related disorders: prevalence and clinical significance. J Am Acad Dermatol. 1998;38(4):555–8.
Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med. 1996;101(6):576–83.
Knapik-Kordecka M, Wysokinski WE. Clinical spectrum of Raynaud’s phenomenon in patients referred to vascular clinic. Cardiovasc Surg. 2000;8(6):457–62.
Caccavo D, Del Porto F, Garzia P, Mitterhofer AP, Galluzzo S, Rigon A, et al. Raynaud’s phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association? Ann Rheum Dis. 2003;62(10):1003–5.
Sanna G, Bertolaccini M, Mameli A, Hughes G, Khamashta M, Mathieu A. Antiphospholipid antibodies in patients with scleroderma: prevalence and clinical significance. Ann Rheum Dis. 2005;64(12):1795–6.
Marie I, Jouen F, Hellot MF, Levesque H. Anticardiolipin and anti-beta2 glycoprotein I antibodies and lupus-like anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol. 2008;158(1):141–4.
Boin F, Franchini S, Colantuoni E, Rosen A, Wigley FM, Cascio-Rosen L. Independent association of anti–β2glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum. 2009;60(8):2480–9.
Herrick AL, Heaney M, Hollis S, Jayson MI. Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia. Ann Rheum Dis. 1994;53(8):540–2.
Vaidya S, Logan JW. Anti-cardiolipin antibodies, Raynaud’s phenomenon with digital ischemia, and nonsmall cell carcinoma of the lung. Scand J Rheumatol. 2001;30(3):172–4.
Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost. 2008;34(3):282–5.
Tolosa-Vilella C, Ordi-Ros J, Vilardell-Tarres M, Selva-O’Callaghan A, Jordana-Comajuncosa R. Raynaud’s phenomenon and positive antinuclear antibodies in a malignancy. Ann Rheum Dis. 1990;49(11):935–6.
Zuber M. Positive antinuclear antibodies in malignancies. Ann Rheum Dis. 1992;51(4):573–4.
Poszepczynska-Guigné E, Viguier M, Chosidow O, Orcel B, Emmerich J, Dubertret L. Paraneoplastic acral vascular syndrome: epidemiologic features, clinical manifestations, and disease sequelae. J Am Acad Dermatol. 2002;47(1):47–52.
Nielsen BL, Petri C. Peripheral symmetrical gangrene in association with metastasizing carcinoma of the colon. Nord Med. 1963;21:237–9.
Wytock DH, Bartholomew LG, Sherps SG. Digital ischaemia associated with small bowel malignancy. Gastroenterology. 1983;84:1025–7.
Friedman SA, Bienenstock H, Richter IH. Malignancy and arteriopathy. Angiology. 1969;20(3):136–43.
Field J, Lane IF. Carcinoma of the lung presenting with digital ischaemia. Thorax. 1986;41(7):573–4.
Wilmalaratna HSK, Sachdev D. Adenocarcinoma of the lung presenting with Raynaud’s phenomenon, digital gangrene and multiple infarctions of the internal organs. Br J Rheumatol. 1987;26(6):473–5.
Arrowsmith JE, Woodhead MA, Bevan DH, Nanson EM, Cummin AR. Digital gangrene in small cell lung cancer: response to aspirin treatment. Thorax. 1991;46(1):63–4.
Kopterides P, Tsavaris N, Tzioufas A, Pikazis D, Lazaris A. Digital gangrene and Raynaud’s phenomenon as complications of lung adenocarcinoma. Lancet Oncol. 2004;5(9):549.
Madabhavi I, Revannasiddaiah S, Rastogi M, Gupta MK. Paraneoplastic Raynaud’s phenomenon manifesting before the diagnosis of lung cancer. BMJ Case Rep 2012; doi: 10.1136/bcr.03.2012.5985.
Onitilo AA, Demos-Bertrand J, Depke J, Resnick JM, Engel J. Digital ischemia as a paraneoplastic consequence of squamous cell lung carcinoma. WMJ. 2012;111(3):138–41.
Andrasch RH, Bardana Jr EJ, Porter JM, Pirofsky B. Digital ischemia and gangrene preceding renal neoplasm. An association with sarcomatoid adenocarcinoma of the kidney. Arch Intern Med. 1976;136(4):486–8.
Boreinstein A, Seidman DS, Ben-Ari GY. Case report: Raynaud’s phenomenon as a presenting sign of metastatic melanoma. Am J Med Sci. 1990;300:41–2.
Hebbar S, Thomas GA. Digital ischemia associated with squamous cell carcinoma of the esophagus. Dig Dis Sci. 2005;50(4):691–3.
Smith RA, Propper DJ, Harvey AR. Ovarian carcinoma and Raynaud’s phenomenon. Br J Dermatol. 1995;132(1):152–3.
Chow SF, McKenna CH. Ovarian cancer and gangrene of the digits: case report and review of the literature. Mayo Clin Proc. 1996;71(3):253–8.
Maurice PDL. Ovarian carcinoma and digital ischaemia. Clin Exp Dermatol. 1996;21(5):381–2.
Legrain S, Raguin G, Piette JC. Digital necrosis revealing ovarian cancer. Dermatology. 1999;199(2):183–4.
Murashima A, Takasaki Y, Hashimoto H, Hirano T, Hirose S. A case of Raynaud’s disease with uterine cancer producing interleukin-6. Clin Rheumatol. 1992;11(3):410–2.
Mahler V, Neureiter D, Kirchner T, Schuler G, Fartasch M. Digital ischemia as paraneoplastic marker of metastatic endometrial carcinoma. Hautarzt. 1999;50(10):748–52.
D’Hondt L, Guillaume TH, Moriau M, Lachapelle JM, Symann M. Digital necrosis associated with chronic myeloid leukemia: a rare paraneoplastic phenomenon. Acta Clin Belg. 1995;50(5):297–300.
Powel KR. Raynaud’s phenomenon preceding acute lymphocytic leukemia. J Pediatr. 1973;83(3):539–40.
Ohtsuka T, Yamakage A, Yamazaki S. Digital ulcers and necroses: novel manifestations of angiocentric lymphoma. Br J Dermatol. 2000;142(5):1013–6.
Smith P, Rice M, Ricci N, Toogood I, Roberton D. A case of Burkitt’s lymphoma presenting with digital ischaemia. Acta Paediatr. 1993;82(2):217–9.
Halpern SM, Todd P, Kirby JD. Hodgkin’s disease presenting with digital ischaemia. Clin Exp Dermatol. 1994;19(4):330–1.
Solak Y, Aksoy S, Kilickap S, Celik I. Acrocyanosis as a presenting symptom of Hodgkin lymphoma. Am J Hematol. 2006;81(2):151–2.
Stavem P, Rorvik T, Brandtzaeg P, Brosstad F, Nordhagen R, Grabner P. Gastric lymphoma causing granulocytopenia and cold intolerance with recovery after treatment. J Intern Med. 1991;229(2):193–6.
Garioch JJ, Todd P, Soukop M, Thomson J. T-cell lymphoma presenting with severe digital ischaemia. Clin Exp Dermatol. 1991;16(3):202–3.
Setoyama M, Yamamoto S, Kanzaki T. Adult T-cell leukaemia/lymphoma presenting with digital gangrene. Dermatology. 1997;195(2):150–2.
Courtney PA, Sandhu S, Gardiner PV, Bell AL. Resolution of digital necrosis following treatment of multiple myeloma. Rheumatology (Oxford). 2000;39(10):1163–4.
Rigdon EE. Trousseau’s syndrome and acute arterial thrombosis. Cardiovasc Surg. 2000;8(3):214–8.
Westbury CB, Harrington KJ, Rhys-Evans P, Archer DJ, Searle AE, Henk JM, Nutting CM, et al. Raynaud’s phenomenon after radical radiotherapy for tumours of the head and neck. Postgrad Med J. 2003;79(929):176–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Anderson, M., Hughes, M. (2015). Other Secondary Causes. In: Wigley, F., Herrick, A., Flavahan, N. (eds) Raynaud’s Phenomenon. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1526-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1526-2_10
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-1525-5
Online ISBN: 978-1-4939-1526-2
eBook Packages: MedicineMedicine (R0)